NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of TransEnterix, Inc. (NYSE:TRXC) resulting from allegations that TransEnterix may have issued materially misleading business information to the investing public.
On April 20, 2016, TransEnterix announced during aftermarket hours that the United States Food and Drug Administration has determined that its SurgiBot™ System does not meet the criteria for substantial equivalence based upon the data and information TransEnterix submitted in its 510(k) submission. On this news, shares of TransEnterix fell $2.47 per share or over 52% to close at $2.27 per share on April 21, 2016.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by TransEnterix investors. If you purchased shares of TransEnterix on or before April 20, 2016, please visit the firm’s website at http://www.rosenlegal.com/cases-883.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.